NasdaqGS - Delayed Quote • USD
Biogen Inc. (BIIB)
At close: April 18 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,835,600.00
9,835,600.00
10,173,400.00
10,981,700.00
13,444,600.00
Cost of Revenue
2,533,400.00
2,533,400.00
2,278,300.00
2,109,700.00
1,805,200.00
Gross Profit
7,302,200.00
7,302,200.00
7,895,100.00
8,872,000.00
11,639,400.00
Operating Expense
5,471,100.00
5,471,100.00
4,993,200.00
6,064,000.00
7,193,100.00
Operating Income
1,831,100.00
1,831,100.00
2,901,900.00
2,808,000.00
4,446,300.00
Net Non Operating Interest Income Expense
29,600.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
Other Income Expense
-563,900.00
-563,900.00
847,200.00
-820,200.00
781,700.00
Pretax Income
1,296,800.00
1,296,800.00
3,591,800.00
1,745,200.00
5,047,500.00
Tax Provision
135,300.00
135,300.00
632,800.00
52,500.00
992,300.00
Earnings from Equity Interest Net of Tax
--
--
2,600.00
34,900.00
5,300.00
Net Income Common Stockholders
1,161,100.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Diluted NI Available to Com Stockholders
1,161,100.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Basic EPS
8.02
8.02
20.96
10.44
24.86
Diluted EPS
7.97
7.97
20.87
10.40
24.80
Basic Average Shares
144,700.00
144,700.00
145,300.00
149,100.00
160,900.00
Diluted Average Shares
145,600.00
145,600.00
146,000.00
149,600.00
161,300.00
Total Operating Income as Reported
--
--
--
2,840,700.00
4,550,100.00
Total Expenses
8,004,500.00
8,004,500.00
7,271,500.00
8,173,700.00
8,998,300.00
Net Income from Continuing & Discontinued Operation
1,161,100.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Normalized Income
1,663,218.40
1,663,218.40
2,340,484.80
2,346,262.00
3,375,223.60
Interest Income
276,500.00
276,500.00
89,300.00
11,000.00
42,000.00
Interest Expense
246,900.00
246,900.00
246,600.00
253,600.00
222,500.00
Net Interest Income
29,600.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
EBIT
1,543,700.00
1,543,700.00
3,838,400.00
1,998,800.00
5,270,000.00
EBITDA
2,038,500.00
2,038,500.00
4,356,800.00
2,880,100.00
5,734,800.00
Reconciled Cost of Revenue
2,279,200.00
2,279,200.00
2,125,800.00
2,503,300.00
1,812,800.00
Reconciled Depreciation
494,800.00
494,800.00
518,400.00
487,700.00
457,200.00
Net Income from Continuing Operation Net Minority Interest
1,161,100.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Total Unusual Items Excluding Goodwill
-560,400.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Total Unusual Items
-560,400.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Normalized EBITDA
2,598,900.00
2,598,900.00
3,499,500.00
3,694,700.00
4,956,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-58,281.60
-58,281.60
150,884.80
-24,438.00
153,423.60
12/31/2020 - 9/17/1991
Yahoo Finance Plus Essential access required. Unlock Access
Related Tickers
GILD Gilead Sciences, Inc.
66.16
-1.15%
AMGN Amgen Inc.
262.75
-0.50%
BMY Bristol-Myers Squibb Company
48.30
+0.96%
MRK Merck & Co., Inc.
125.23
-0.11%
AZN AstraZeneca PLC
68.36
-0.25%
LLY Eli Lilly and Company
745.95
-0.64%
ABBV AbbVie Inc.
164.66
+0.25%
SNY Sanofi
45.39
-1.56%
NVS Novartis AG
92.57
-0.55%
PFE Pfizer Inc.
25.39
-0.12%